Shots:
- The US FDA has received sNDA of Venclexta (venetoclax) & acalabrutinib in previously untreated patients with chronic lymphocytic leukemia (CLL)
- sNDA was supported by AstraZeneca-sponsored P-III (AMPLIFY) trial assessing Venclexta + acalabrutinib ± Obinutuzumab vs chemoimmunotherapy in previously untreated CLL pts without del(17p) or TP53 mutation
- Trial showed that Venclexta + acalabrutinib a 35% reduction in the risk of disease progression or death, showing improved PFS vs chemoimmunotherapy; data was presented at ASH 2024
Ref: AbbVie | Image: AbbVie | Press Release
Related News:- AbbVie Reports Topline P-III (UP-AA) Trial Data on Rinvoq (Upadacitinib) to Treat Alopecia Areata
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
